Special Issue

Therapeutic Potential of Nerve Growth Factor Signaling Blockers against Castration-Resistant Prostate Cancers

Message from the Guest Editor

Recent studies have demonstrated that activated NGF signaling mediates treatment-mediated neuroendocrine transformation, an advanced CRPC sub-phenotype with high mortality and low responding rate to conventional treatment. Furthermore, gastroenteropancreatic neuroendocrine patients benefit from receiving NGF signaling blockers and immune checkpoint inhibitors. Additionally, the NGF receptor inhibitor reduces the tumor growth of androgen-independent prostate cancer cell lines in vitro. These studies imply that modulating the activity of NGF signaling may benefit the tumor control of CRPC and neuroendocrine tumors, which is not evaluated yet. This Special Issue aims to collect studies on the therapeutic potential of NGF blockers on CRPC, such as the discovery of new NGF blockers or combinations, clinical trials of NGF signaling blockers against CRPCs, and reviews for stratifying CRPC patients with clinical benefit from NGF signaling blockers.

Guest Editor

Dr. Shian-Ren Lin
FullHope Biomedical Co. Ltd., New Taipei City, 241405, Taiwan

Deadline for manuscript submissions

closed (31 October 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed

mdpi.com/si/144214

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).